Diana Ernst, RPh

Editorial Director https://www.endocrinologyadvisor.com

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Diabetes

Aflibercept Now Available in Single-Dose Prefilled Syringe

Diana Ernst, RPh

December 13, 2019

The prefilled syringe requires fewer preparation steps than the vial.

Diabetes

First Generics of Lyrica Get FDA Approval

Diana Ernst, RPh

July 24, 2019

Pregabalin is a Schedule V controlled substance.

Cardiovascular and Metabolic Disorders

FDA Approves Sprinkle Formulation of Rosuvastatin

Diana Ernst, RPh

July 18, 2019

Ezallor Sprinkle is intended for patients who have difficulty swallowing.

Type 1 Diabetes

FDA Rejects Dapagliflozin sNDA for Type 1 Diabetes

Diana Ernst, RPh

July 15, 2019

Dapagliflozin was recently approved for T1D in Europe and Japan.

Type 2 Diabetes

Empagliflozin Fast-Tracked for Chronic Heart Failure Indication

Diana Ernst, RPh

June 27, 2019

The FDA has granted Fast Track designation to empagliflozin for the reduction of the risk of cardiovascular death and hospitalization in patients with chronic heart failure.

Indication(s): As adjunct to diet and exercise, to improve glycemic control in type 2 diabetes.

Pediatric Endocrinology

Liraglutide Approved for Pediatric Patients With Type 2 Diabetes

Diana Ernst, RPh

June 18, 2019

The approval of Victoza in this patient population was based on data from the ELLIPSE trial which included 134 children and adolescents.

General Endocrinology

Progestin-Only Contraceptive Slynd Gets FDA Approval

Diana Ernst, RPh

June 3, 2019

Slynd contains drospirenone, a spironolactone analogue.

Cardiovascular and Metabolic Disorders

Icosapent Ethyl Receives Priority Review for CV Risk Reduction Indication

Diana Ernst, RPh

May 31, 2019

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for Vascepa (icosapent ethyl; Amarin) to reduce residual cardiovascular.

Cardiovascular and Metabolic Disorders

Updated NLA Guidance Identifies Patients in Which PCSK9i Use Provides Reasonable Value

Diana Ernst, RPh

May 20, 2019

The National Lipid Association (NLA) has released updated guidance for clinicians on identifying patients for which proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor therapy would provide reasonable value. Currently, two PCSK9 therapies have been approved by the Food and Drug Administration. Alirocumab is indicated as an adjunct to diet, alone or in combination with…

Diabetes

Eylea Approved for the Treatment of Diabetic Retinopathy

Diana Ernst, RPh

May 14, 2019

The Food and Drug Administration (FDA) has approved Eylea (aflibercept; Regeneron) for the treatment of diabetic retinopathy.

Next post in Diabetes